Jeff E. Knight
CIK 1881007 · Chief Dev & Operating Officer · last filed 2026-04-17
Jeff E. Knight is a Chief Dev & Operating Officer who has filed 26 SEC Form 4 insider transactions across 2 companies since 2021. The most recent filing, for CRNX, was dated Jul 2, 2026. Across all open-market trades the lifetime net is −$7.0M, making them a net seller over the disclosed history.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
CRNX price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
6055 LUSK BOULEVARD
SAN DIEGO, CA 92121
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ALXO | Chief Dev & Operating Officer | — | $1.13 | — | $0 | 1 | 2026-04-17 |
| Crinetics Pharmaceuticals, Inc. (CRNX) Delisted | Chief Dev. & Operating Officer | 190,452 | $84.95 | $16.18M | -$7.04M | 16 | 2026-04-10 |
Recent Filings
26 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-07-02 | Crinetics Pharmaceuticals, Inc. (CRNX) Delisted | Notice (144) | −47,420 | -$1.83M | EDGAR |
| 2026-05-04 | Crinetics Pharmaceuticals, Inc. (CRNX) Delisted | Notice (144) | −9,485 | -$370.1K | EDGAR |
| 2026-04-17 | ALXO | Grant (A) | — | $0 | EDGAR |
| 2026-04-14 | Crinetics Pharmaceuticals, Inc. (CRNX) Delisted | Notice (144) | −20,900 | -$808.0K | EDGAR |
| 2026-04-13 | Crinetics Pharmaceuticals, Inc. (CRNX) Delisted | Notice (144) | −4,434 | -$174.9K | EDGAR |
| 2026-04-10 | Crinetics Pharmaceuticals, Inc. (CRNX) Delisted | Mixed | −6,729 | -$1.66M | EDGAR |
| 2026-04-08 | Crinetics Pharmaceuticals, Inc. (CRNX) Delisted | Notice (144) | −85,163 | -$3.27M | EDGAR |
| 2026-03-18 | Crinetics Pharmaceuticals, Inc. (CRNX) Delisted | Sell (S) | −9,911 | -$370.4K | EDGAR |
| 2026-03-16 | Crinetics Pharmaceuticals, Inc. (CRNX) Delisted | Notice (144) | −25,113 | -$941.5K | EDGAR |
| 2026-02-25 | Crinetics Pharmaceuticals, Inc. (CRNX) Delisted | Grant (A) | +34,000 | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.